Ispire Technology Inc.

ISPR
About the company

Ispire Technology Inc. researches, develops, designs, commercializes, sells, markets, and distributes e-cigarettes and cannabis vaping products worldwide under the Ispire and Aspire brands. The company was founded in 2010 and is headquartered in Los Angeles, California. Ispire Technology Inc. is a subsidiary of Pride Worldwide Investment Limited.

Country: United StatesPrice: $1.69Market Cap: $97.6M

Investment snapshot

0%positive consensus
Scored 1d ago

Positive

0

BUY / PASS

Neutral / negative

2 / 14

NEUTRAL / FAIL

Median fair value

—

No comparable estimates

Models with upside

0 / 17

Positive margin of safety

Key risk

No clean pass — all 16 investors flag at least one profitability criterion

Framework analysis

VerdictMeaning
BUYPositive purchase signal: the framework's buy requirements are met.
PASSThe company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state.
NEUTRALNeither a positive nor negative conclusion. It does not mean to hold an existing position.
FAILThe company does not clear the framework's requirements.
RankedRanked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL.

Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.

MetricGraham

Defensive Value

Buffett

Quality Compounder

Lynch

GARP

Greenblatt

Magic Formula

Piotroski

F-Score

Dreman

Contrarian Value

Munger

Quality Focus

Pabrai

Dhandho Framework

Akre

Three-Legged Stool

Marks

Risk-Aware Value

Ackman

Activist Value

Templeton

Global Bargain Hunter

Sleep

Scale Economies Shared

Asness

Systematic Factors

Neff

Low-P/E Total Return

Schloss

Asset-Value Discipline

O'Shaughnessy

Systematic Factor Composite

VerdictFAILFAILFAILNot rankedFAILFAILFAILFAILFAILFAILFAILFAILFAILNEUTRALFAILFAILNEUTRAL
Score
AnalysisChecking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…
Intrinsic Value (annual)N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Margin of SafetyN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Financial Basis

TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Annual history · FY 2025

Latest source filing: 2026-11-09

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2025-09-15

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 vs 2025-09-30 · TTM ended 2026-09-30

Latest source filing: 2026-11-09

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2025-09-15

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2025-09-15

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Market data at 2026-11-01

Latest source filing: 2026-11-09

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025

Latest source filing: 2025-09-15

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025

Latest source filing: 2025-09-15

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2025-09-15

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2025-09-15

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 · Market data at 2026-11-01

Latest source filing: 2026-11-09

Score computed: 2026-11-14

Annual history · FY 2025 · Price history 2025-01-01–2026-11-01

Latest source filing: 2025-09-15

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2025-09-15

Score computed: 2026-11-14

TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Price history 2025-01-01–2026-11-01 · Annual history · FY 2025

Latest source filing: 2026-11-09

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2025-09-15

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-09-30

Latest source filing: 2026-11-09

Score computed: 2026-11-14

TTM ended 2026-09-30 · Annual history · FY 2025 · Price history 2025-01-01–2026-11-01

Latest source filing: 2026-11-09

Score computed: 2026-11-14

Where It Passes

    Where It Falls Short

    • Profitability0% pass✓ 1✗ 34▾

      No clean pass — all 16 investors flag at least one profitability criterion

      Positive EPS (10 years)0/6 years positive
      ✗GrahamPositive EPS every year for 10 years
      EPS Growth (3-yr avg, 10-yr window)N/A (negative base EPS)
      ✗Graham>= 33% growth
      Net Income Positive (10+ years)0/6 years positive
      ✗BuffettPositive every year for 10+ years
      ROE (up to 5-year arithmetic mean)-2611.3%
      ✗Buffett> 15% arithmetic mean (app rule)
      Operating Margin (10-yr trend)-29.7% (latest)
      ✗BuffettStable or rising over 10 years
      Free Cash Flow Proxy$-39.5M
      ✗BuffettPositive and growing
      Earnings Variance (10-yr CoV)N/A (negative mean EPS)
      ✗BuffettCoV < 0.3
      Retained Earnings Effectiveness
      ✗Buffett$1 retained -> > $1 market value created
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      3-5 Year EPS CAGR
      ✗Lynch15-30% (Fast Grower); > 0% to pass
      ROEN/A (negative equity)
      ✗Lynch> 15%
      EBIT / Enterprise Value-51.7%
      ✗Greenblatt> 10%
      Earnings Yield + ROC AssessmentEY=-51.7%, ROC=N/A (invested capital <= 0)
      ✗GreenblattBoth EY > 10% and ROC > 25%
      Net Income / Total Assets-38.39%
      ✗PiotroskiROA > 0
      ROA Change YoY-38.39% -> -38.39% (delta: +0.00%)
      ✗PiotroskiCurrent ROA > Prior ROA
      (CFO / Total Assets) vs ROACFO/Assets=-7.21%, ROA=-38.39%
      ✓PiotroskiCFO/Assets > ROA
      Gross Margin Change YoY17.8% -> 17.8%
      ✗PiotroskiImproved YoY
      Pre-Tax Income / Revenue-38.0%
      ✗Dreman>= 8%
      Net Income / Shareholders' Equity
      ✗Dreman> 12%
      Margin of SafetyP/B=160.1x
      ✗PabraiP/B < 1.5 or P/E < 15
      Return on Equity-4340.5% (3-yr avg)
      ✗AkreROE > 20% (3-year avg)
      Discount to Intrinsic ValueN/A (negative normalized EPS)
      ✗Marks>= 20% below intrinsic value
      Positive Net Income Frequency0/5 years positive
      ✗MarksPositive net income in >= 7 of last 10 years
      Operating Income / Revenue-38.7%
      ✗Ackman>= 15%
      Net Income / Shareholders Equity
      ✗Ackman>= 15%
      5-Year EPS CAGR
      ✗Templeton> 0% (5-year EPS CAGR)
      Operating Margin Trend-9.1% (2023) -> -29.7% (2025)
      ✗TempletonNon-negative operating-margin trend over 3 years
      Revenue growth vs. gross and operating margin trendgross margin 19.6% -> 17.8%, operating margin -9.1% -> -29.7%
      ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
      Net income / market capitalization-37.27%; #4921/6340 (top 77.6%)
      ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
      Gross profit / total assets+21.97%; #1931/3702 (top 52.2%)
      ✗AsnessTop 30% of eligible cross-section
      Net income / positive book equity
      ✗AsnessTop 30% of eligible cross-section
      Negative 5-year standard deviation of ROA-0.1578; #3989/5884 (top 67.8%)
      ✗AsnessTop 30% of eligible cross-section
      3-5 Year Diluted EPS CAGR
      ✗Neff7%-20% annualized
      Positive Diluted-EPS Years0/5 years positive
      ✗Schloss>= 70% positive over 5-10 observed years (app rule)
    • Valuation0% pass✗ 28▾

      All 13 investors flag ISPR's valuation

      Price / 3-yr avg EPS
      ✗Graham<= 15x
      Price-to-Book Ratio160.1x
      ✗Graham<= 1.5x
      P/E x P/B
      ✗Graham<= 22.5
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      EBIT / Enterprise Value-51.7%
      ✗Greenblatt> 10%
      Earnings Yield + ROC AssessmentEY=-51.7%, ROC=N/A (invested capital <= 0)
      ✗GreenblattBoth EY > 10% and ROC > 25%
      Price / EPS
      ✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)
      Price / (CFO / Shares)N/A (negative CFPS)
      ✗Dreman< 8x
      Price / Book Value per Share160.1x
      ✗Dreman< 1.2x✗Templeton< 1.5x✗SchlossP/B <= 0.80x (app cutoff)
      Valuation ReasonablenessOE Yield=-40.8%
      ✗MungerP/E < 25 or Owner Earnings Yield > 5%
      P/E or FCF YieldFCF Yield=-8.7%
      ✗PabraiP/E < 15 or FCF Yield > 10%
      P/B or P/E vs. Historical AverageP/B=160.1x
      ✗MarksP/E < 15 or P/B < 2.0
      Discount to Intrinsic ValueN/A (negative normalized EPS)
      ✗Marks>= 20% below intrinsic value
      Price / FCF per ShareN/A (negative FCF)
      ✗Ackman<= 25
      Price vs. Trailing Low130% of trailing low ($1.30)
      ✗Templeton<= 120% of trailing low (certified split-adjusted live window)
      Net income / market capitalization-37.27%; #4921/6340 (top 77.6%)
      ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
      Positive book equity / market capitalization-0.3569; #5906/6449 (top 91.6%)
      ✗AsnessTop 30% of eligible cross-section
      Price / Diluted EPS
      ✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)
      (EPS CAGR % + Dividend Yield %) / P/E
      ✗Neff> 0.7 (Neff's published traditional edge)
      Price / Tangible Book Value per Share160.08x
      ✗SchlossP/TBV <= 1.00x (app cutoff)
      Book Value per Share Change-95.5%
      ✗SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)
      Revenue / market capitalization+0.9547; #1814/5247 (top 34.6%)
      ✗OshaughnessyTop 10% of eligible cross-section
      (Operating cash flow - capex) / market capitalization-8.68%; #3181/4519 (top 70.4%)
      ✗OshaughnessyTop 10% of eligible cross-section
      Trailing six-month price return through the evaluation date-3.43%; #3037/6202 (top 49.0%)
      ✗OshaughnessyTop 10% of eligible cross-section
    • Cash Flow0% pass✓ 1✗ 11▾

      No clean pass — all 10 investors flag at least one cash flow criterion

      Free Cash Flow Proxy$-39.5M
      ✗BuffettPositive and growing
      FCF Positive and Growing$-8.5M
      ✗LynchPositive and growing
      Operating Cash Flow$-7.4M
      ✗PiotroskiCFO > 0
      (CFO / Total Assets) vs ROACFO/Assets=-7.21%, ROA=-38.39%
      ✓PiotroskiCFO/Assets > ROA
      Price / (CFO / Shares)N/A (negative CFPS)
      ✗Dreman< 8x
      P/E or FCF YieldFCF Yield=-8.7%
      ✗PabraiP/E < 15 or FCF Yield > 10%
      FCF Positive0/5 years FCF positive
      ✗MarksPositive FCF in majority of recent years
      (OCF - CapEx) / Market Cap-8.8%
      ✗Ackman>= 4%
      Price / FCF per ShareN/A (negative FCF)
      ✗Ackman<= 25
      Positive Operating Cash Flow frequency0/5 years positive
      ✗SleepPositive OCF in >= 70% of available years
      Operating Cash Flow - Capital Expenditures$-8.5M
      ✗Neff> $0 (app proxy for a strong fundamental case)
      (Operating cash flow - capex) / market capitalization-8.68%; #3181/4519 (top 70.4%)
      ✗OshaughnessyTop 10% of eligible cross-section
    • Growth0% pass✓ 1✗ 12▾

      No clean pass — all 8 investors flag at least one growth criterion

      EPS Growth (3-yr avg, 10-yr window)N/A (negative base EPS)
      ✗Graham>= 33% growth
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      3-5 Year EPS CAGR
      ✗Lynch15-30% (Fast Grower); > 0% to pass
      Inventory Growth vs Revenue GrowthInv: -57.9% vs Rev: -21.3%
      ✓LynchInventory growth < Revenue growth
      EPS Growth Direction$-0.04 (2021) -> $-0.69 (2025)
      ✗DremanPositive over recent years
      EPS CAGR
      ✗Dreman> 5% annualized
      Positive Net Income Frequency0/5 years positive
      ✗MarksPositive net income in >= 7 of last 10 years
      3yr Median Revenue Growth0.0%
      ✗Ackman>= 5%
      Positive EPS Growth Frequency0/4 years with positive EPS growth
      ✗AckmanPositive EPS growth in >= 3 of last 5 years
      5-Year EPS CAGR
      ✗Templeton> 0% (5-year EPS CAGR)
      Revenue growth vs. gross and operating margin trendgross margin 19.6% -> 17.8%, operating margin -9.1% -> -29.7%
      ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
      5-year Revenue CAGR
      ✗SleepCAGR > 7%
      3-5 Year Diluted EPS CAGR
      ✗Neff7%-20% annualized
    • Efficiency0% pass✗ 11▾

      All 8 investors flag ISPR's efficiency

      Current Ratio1.01
      ✗Graham>= 2.0
      ROIC (3-5 yr avg)
      ✗Buffett> 10%
      ROIC - WACC
      ✗BuffettPositive (WACC = 10%)
      EBIT / (NWC + Net Fixed Assets)N/A (invested capital <= 0)
      ✗Greenblatt> 25%
      Current Ratio Change YoY1.01 -> 1.01
      ✗PiotroskiIncreased YoY
      Revenue / Total Assets Change YoY1.25x -> 1.25x
      ✗PiotroskiImproved YoY
      Current Assets / Current Liabilities1.01
      ✗Dreman> 1.5
      Return on Invested Capital
      ✗Munger> 15%
      ROIC (high and growing)FY2023: ROIC=unavailable; FY2024: ROIC=unavailable; FY2025: ROIC=unavailable
      ✗AkreLatest 3 consecutive FYs: ROIC > 15% in each
      Reinvestment Rate x ROIC
      ✗AkreReinvestment Rate * ROIC > 10%
      ROIC (5-year)
      ✗SleepROIC > 12% in a majority of years
    • Verdicts0% pass✗ 14▾

      Split decision: 14 FAIL · 2 NEUTRAL

      Overall verdict
      ✗GrahamFAIL (0/9)✗BuffettFAIL (0/9)✗LynchFAIL (1/7)•GreenblattNot ranked✗PiotroskiFAIL (F-Score 3)✗DremanFAIL (0/11)✗MungerFAIL (0/4)✗PabraiFAIL (0/3)✗AkreFAIL (1/6)✗MarksFAIL (0/5)✗AckmanFAIL (1/9)✗TempletonFAIL (1/8)✗SleepFAIL (2/6)•AsnessNEUTRAL (Not ranked)✗NeffFAIL (1/6)✗SchlossFAIL (0/7)•OshaughnessyNEUTRAL (Not ranked)
    • Debt & Leverage8% pass✓ 1✗ 14▾

      11 of 12 flag ISPR's debt & leverage — Graham, Buffett, Lynch +8 more

      LT Debt vs Net Current Assets
      ✗GrahamLT Debt <= Net Current Assets
      Debt/Equity & Interest Coverage
      ✗BuffettD/E < 0.5 AND Interest Coverage > 5x
      Total Debt / Equity
      ✗Lynch< 0.33
      Cash - Long-term Debt
      ✗LynchPositive preferred
      LT Debt / Total Assets Change0.00% -> 0.00%
      ✓PiotroskiDecreased YoY
      Current Assets / Current Liabilities1.01
      ✗Dreman> 1.5✗SchlossCurrent ratio >= 1.50x (app cutoff)
      Total Debt / Shareholders' Equity
      ✗Dreman< 0.8✗Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✗SchlossD/E < 1.00x
      Debt Levels
      ✗MungerDebt/Equity < 0.5✗AkreDebt/Equity < 0.3
      Interest Coverage & Debt/EBITDAIC=-251.9x, D/EBITDA=N/A
      ✗MarksInterest Coverage > 3x; Debt/EBITDA < 4x
      Total Debt / Shareholders Equity
      ✗Ackman<= 1.0
      Negative debt-to-equity (higher means less debt)
      ✗AsnessTop 30% of eligible cross-section

    Business & financials

    Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.

    Company Profile

    Industry: Tobacco Products
    Size: Micro Cap($97.6M)
    Revenue: $127.5M+0.0% YoY
    Net Income: $39.2M+0.0% YoY

    Financial Snapshot

    Operating Margin-29.7%
    Return on Equity-6489.3%
    Debt / Equity--
    Current Ratio1.01
    EPS (Diluted)$-0.69
    Shares Retired−0.1% / −1.4% 2y

    Shareholder Return

    Fiscal 2025

    Issued 0.1% of shares last year, 1.4% issued over two.

    Buybacks
    —
    Dividends
    —

    Company Financials

    Latest TTM and quarters alongside annual years

    TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.

    The latest annual period end is unavailable. Showing the latest fiscal cycle’s quarters; quarter and annual columns may overlap. Quarterly shows the full quarter history.

    MetricTTM · 2026-09-30

    2025-10-01 – 2026-09-30

    Sources · derived quarter values

    Derived from cumulative filings: operating cash flow, depreciation amortization, capex, buybacks, revenue, net income, operating income, gross profit, ebit, pre tax income, interest expense.

    Q1 FY 2027

    2026-07-01 – 2026-09-30

    Sources
    FY 2025
    Sources
    • 10-K · 2025-09-15
    FY 2024
    Sources
    • 10-K · 2025-09-15
    FY 2023
    Sources
    • 10-K · 2024-09-27
    FY 2022
    Sources
    • 10-K · 2023-09-19
    FY 2021
    Sources
    • 10-K · 2023-09-19
    Market Cap$97.6Mcurrent--$210.8Mest.$273.2Mest.$623.1Mest.$491.5Mest.--
    Revenue$93.2M↓21%$27.5M↓9%$127.5M$127.5M↓16%$151.9M↑31%$115.6M↑31%$88.1M
    Operating Income-$36.0M↓2%-$6.1M↓128%-$37.8M-$37.8M↓172%-$13.9M↓211%-$4.5M↓353%-$988.7K
    Net Income-$36.4M↑1%-$6.4M↓98%-$39.2M-$39.2M↓166%-$14.8M↓146%-$6.0M↓220%-$1.9M
    EPS (Diluted)--$-0.11↓83%$-0.69$-0.69↓156%$-0.27↓125%$-0.12↓200%$-0.04
    Gross Margin12.5%↓27%16.2%↓5%17.8%17.8%↓9%19.6%↑9%18.0%↑19%15.1%
    Operating Margin-38.7%↓30%-22.3%↓151%-29.7%-29.7%↓225%-9.1%↓136%-3.9%↓245%-1.1%
    ROE104.4%↓95%—-6489.3%-6489.3%↓15041%-42.9%↓125%-19.1%↓20%-15.9%
    Total Debt--------------
    Shareholders' Equity-$34.8M↓1870%-$34.8M↓1870%$604.7K$604.7K↓98%$34.5M↑9%$31.5M↑167%$11.8M
    Current Ratio1.01↓11%1.01↓11%1.011.01↓16%1.19↓21%1.52↑36%1.12
    Debt / Equity———————
    Operating Cash Flow-$1.0M↑92%-$1.6M↓37%-$7.4M-$7.4M↑60%-$18.3M↓116%-$8.5M↓12%-$7.6M
    Free Cash Flow---$1.6M↓36%-$8.5M-$8.5M↑58%-$20.3M↓114%-$9.5M↓23%-$7.7M

    Score history

    Historical Score Timeline

    Industry peers

    Industry Peers

    Similar companies in Tobacco Products

    ISPR vs Peers — Financial Grading

    Revenue$127.5MMedian
    Net Income$39.2MBottom 25%
    ROE-6489.3%Bottom 25%
    D/E—
    Op. Margin-29.7%Median
    Curr. Ratio1.01Median
    CompanyMarket CapPriceRevenueNet IncomeROED/EOp. MarginCurr. RatioGrahamBuffettLynchGreenblattPiotroskiDreman
    Philip Morris International Inc.PM$310.1B$198.96$40.6B$11.3B-113.5%-4.8736.6%0.964/97/93/71/3F-Score 73/11
    British American Tobacco p.l.c.BTI$132.9B$61.89$34.5B$10.5B16.9%0.7639.0%0.871/90/93/70/3F-Score 64/11
    ALTRIA GROUP, INC.MO$130.8B$78.64$23.3B$6.9B-198.4%-7.3442.5%0.653/95/91/70/3F-Score 64/11
    RLX Technology Inc.RLX$1.9B$1.56$572.8M$133.4M5.9%0.018.3%5.704/91/92/70/3F-Score 87/11
    Turning Point Brands, Inc.TPB$1.1B$55.55$463.1M$58.2M15.6%0.8020.6%5.563/95/92/71/3F-Score 64/11
    Healthier Choices Management Corp.HCMC$26.4M$0.00$34741.00$7.0M568.9%—-20243.9%0.840/90/90/70/3F-Score 40/11
    22nd Century Group, Inc.XXII$424,215$0.77$17.6M$5.1M-32.1%0.04-65.8%2.423/91/92/70/3F-Score 43/11